NEW YORK (GenomeWeb News) - Xenomics said today it has granted a co-exclusive license to Asuragen to use the NPM1 gene to develop diagnostic products for acute myeloid leukemia patients.
 
Under the sub-license agreement, Asuragen will have access to use the nucleophosmin gene, or NPM1, toward developing tests to diagnose, stratify, and monitor AML patients.
 
Xenomics holds exclusive rights to a recent discovery at the University of Perugia that has shown that many AML patients have mutations in that gene.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.

A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.

In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.